MYoncology Direct To Site Distribution
DIRECT TO SITE DISTRIBUTION
In today’s time-critical environment, sponsors are looking for open label trial designs where a drug can be sourced, labeled and distributed directly to a clinical site. Myoderm delivers Direct to Clinical Sites capabilities with a time-sensitive focus. That’s how we work. For every Direct to Clinical Sites project for every phase of development with your patients needs in mind.
Our DTS management style. Forward. Thinking.
With super-fast Phase I startup through Phase II and Phase III and expanded access support, we take the lead from start to finish – from obtaining all trial supply needed to labeling through distribution to all your clinical sites.
Managing a DTS product with TLC.
Many Direct to Clinical Sites projects require a high level of expertise, as you can’t predict disruptions like a product recall or uncertainty on the total product to order. That’s why we are flexible, yet fastidious with Direct to Clinical Sites assignments. Our can-do attitude and personalized attention have saved sponsors significant amounts of time and money.
A passion to supply compassionate use drugs.
Our global connections and experience in securing hard-to-find products enables us to supply Compassionate Use drugs at a moment’s notice and to put a plan in action to ensure continued product supply for patients at the culmination of a study.
Unmatched insights. Direct to site.
Our Direct to Clinical Sites capabilities are driven by the need to think and act quickly to oversee the complex details and cost parameters in managing your clinical supplies. Our global network and local resources result in Direct to Clinical Sites services that accelerate product delivery to trial sites worldwide.